BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 100 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $685,000 | -37.7% | 84,855 | -41.1% | 0.01% | -25.0% |
| Q3 2018 | $1,099,000 | +33.2% | 144,000 | 0.0% | 0.01% | +33.3% |
| Q2 2018 | $825,000 | +20.1% | 144,000 | 0.0% | 0.01% | +20.0% |
| Q1 2018 | $687,000 | -2.8% | 144,000 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $707,000 | -6.4% | 144,000 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $755,000 | -5.7% | 144,000 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $801,000 | -33.8% | 144,000 | 0.0% | 0.01% | -37.5% |
| Q1 2017 | $1,210,000 | +32.7% | 144,000 | 0.0% | 0.01% | +33.3% |
| Q4 2016 | $912,000 | +29.2% | 144,000 | -10.0% | 0.01% | +20.0% |
| Q3 2016 | $706,000 | +55.5% | 160,000 | 0.0% | 0.01% | +66.7% |
| Q2 2016 | $454,000 | +0.2% | 160,000 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $453,000 | – | 160,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 7,637,700 | $77,675,000 | 7.44% |
| Burrage Capital Management LLC | 864,916 | $8,796,000 | 7.13% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,367,670 | $24,079,000 | 3.61% |
| HealthCor Management, L.P. | 4,886,440 | $49,695,000 | 1.76% |
| Ghost Tree Capital, LLC | 500,000 | $5,085,000 | 1.20% |
| Integral Health Asset Management, LLC | 400,000 | $4,068,000 | 1.16% |
| Lisanti Capital Growth, LLC | 472,520 | $4,806,000 | 0.62% |
| Parkman Healthcare Partners LLC | 244,680 | $2,488,000 | 0.58% |
| Baker Brothers Advisors | 12,710,818 | $129,269,000 | 0.56% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,605,380 | $26,497,000 | 0.56% |